Journal Article

Molecular targets of the chemopreventive agent 1,4-phenylenebis (methylene)-selenocyanate in human non-small cell lung cancer

Karam El-Bayoumy, Arunangshu Das, Bhagavathi Narayanan, Narayanan Narayanan, Emerich S. Fiala, Dhimant Desai, Chinthalapally V. Rao, Shantu Amin and Raghu Sinha

in Carcinogenesis

Volume 27, issue 7, pages 1369-1376
Published in print July 2006 | ISSN: 0143-3334
Published online January 2006 | e-ISSN: 1460-2180 | DOI:
Molecular targets of the chemopreventive agent 1,4-phenylenebis (methylene)-selenocyanate in human non-small cell lung cancer

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics


Show Summary Details


Clinical chemoprevention trials of lung cancer have been somewhat disappointing and the development of highly effective chemopreventive agents is urgently needed. We previously showed that the organoselenium 1,4-phenylenebis(methylene)selenocyanate (p-XSC) is a potent chemopreventive agent in numerous preclinical animal models including a lung tumor model that employs carcinogens found in tobacco smoke. The goal of this study is to define molecular targets that will be highly promising in the design of future chemoprevention trials of non-small cell lung cancer (NSCLC), which is by far the most common type of lung cancer cases. In the present investigation, we showed that p-XSC at several doses (2.5, 5, 10 and 20 μM) including physiological levels (2.5–5.0 μM) of selenium is capable of inhibiting cell growth in a dose-dependent manner and inducing apoptosis in three NSCLC cells (NCI-H460, NCI-1299 and A549). To clarify the mechanism involved at the molecular level, we focused only on NCI-460 cells and examined the effects of p-XSC on markers that are known to be critical in the development of NSCLC. Using western blot analysis, we showed that p-XSC reduced the expression of cyclooxygenase-2 (COX-2) and phospholipase A2 (PLA2); although p-XSC inhibited both Akt and p-Akt but its effect was not significant. Using cDNA microarray approach (3800 genes per array) we found that p-XSC upregulates 22 genes by ≥2-fold while downregulates 13 genes by ≤0.5-fold; these altered genes include transcriptional factors, growth factors and those involved in xenobiotic metabolism as well as pro- and anti-apoptotic genes. Expression of selected genes was confirmed by RT–PCR; p-XSC reduced the levels of COX-2, PLA2, NFB and Cyclin D1 but enhanced the levels of glutathione peroxidase-5. Collectively, the results of this study showed that p-XSC alters several molecular markers in a manner that can account for its inhibitory effect of cell growth and induction of apoptosis; therefore, p-XSC may be considered a promising candidate for clinical chemoprevention of NSCLC.

Keywords: COX-2, cyclooxygenase-2; GPX, glutathione peroxidase; NDUFS3, NADH dehydrogenase (ubiquinone)Fe-S protein 3; NF-κB, Nuclear factor-κB; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NSCLC, non-small cell lung cancer; PI3K, phosphatidylinositol 3-kinase; PLA2, phospholipase A2; p-XSC, 1,4-phenylenebis(methylene)selenocyanate; RT–PCR, Reverse transcription polymerase chain reaction; SCLC, small cell lung cancer

Journal Article.  4844 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.